Volume 14 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. doi: 10.12290/xhyxzz.2023-0023
Citation: QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. doi: 10.12290/xhyxzz.2023-0023

Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN

doi: 10.12290/xhyxzz.2023-0023
Funds:

National Natural Science Foundation of China 81974255

More Information
  •   Objective  To analyze the clinical phenotype and immunological characteristics of a patient with heterozygous mutation of PTEN and enrich the clinical phenotypes related to PTEN mutation.  Methods  A retrospective analysis of the clinical data of a patient with PTEN heterozygous mutation admitted to the Children's Hospital of Chongqing Medical University was conducted. Peripheral venous blood was extracted for medical whole-exome comprehensive detection, and the PTEN mutation was confirmed by Sanger sequencing. Flow cytometry was applied to detect the lymphocyte subsets and immunophenotype of the patient. The expression level of PTEN protein in peripheral blood mononuclear cells was detected by Western blot, and the healthy control was the patient's father.  Results  The patient was a boy of 1 year and 4 months, with macrocephaly (head circumference > P99), verrucous epidermal nevus, delayed psychomotor development and delayed language learning as the main manifestations. Gene sequencing revealed a de novo heterozygous mutation of PTEN c.388C > T(p.R130X). Reduced expression of PTEN protein was observed in peripheral blood mononuclear cells of the patient. For immunological characteristics, the IgA level mildly decreased(0.177 g/L), with increased counts of terminally differentiated memory CD4+ T cells, terminally differentiated memory CD8+ T cells, transitional B cells, but phosphorylation of PI3K/Akt/mTOR pathway in T cells was normal. The patient mainly manifested as PTEN hamartoma tumor syndrome related phenotype, without any classic activated phosphatidylinositol 3-kinase δ syndrome-like phenotype.  Conclusions  This patient has a de novo heterozygous mutation of PTEN c.388C > T(p.R130X), which has not been previously reported in China. This article could enrich clinicians' understanding of the disease and assist clinical diagnosis and treatment.
  • loading
  • [1] Pilarski R. PTEN Hamartoma Tumor Syndrome: A Clinical Overview[J]. Cancers (Basel), 2019, 11: 844. doi:  10.3390/cancers11060844
    [2] Celebi JT, Tsou HC, Chen FF, et al. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN[J]. J Med Genet, 1999, 36: 360-364.
    [3] Tsujita Y, Mitsui-Sekinaka K, Imai K, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency[J]. J Allergy Clin Immunol, 2016, 138: 1672-1680. doi:  10.1016/j.jaci.2016.03.055
    [4] Ding Y, Zhou L, Xia Y, et al. Reference values for peripheral blood lymphocyte subsets of healthy children in China[J]. J Allergy Clin Immunol, 2018, 142: 970-973. doi:  10.1016/j.jaci.2018.04.022
    [5] Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria[J]. J Natl Cancer Inst, 2013, 105: 1607-1616. doi:  10.1093/jnci/djt277
    [6] Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017[J]. J Natl Compr Canc Netw, 2017, 15: 9-20. doi:  10.6004/jnccn.2017.0003
    [7] Busa T, Milh M, Degardin N, et al. Clinical presentation of PTEN mutations in childhood in the absence of family history of Cowden syndrome[J]. Eur J Paediatr Neurol, 2015, 19: 188-192. doi:  10.1016/j.ejpn.2014.11.012
    [8] Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study[J]. J Allergy Clin Immunol, 2017, 139: 597-606. doi:  10.1016/j.jaci.2016.06.021
    [9] Larbi A, Fulop T. From "truly naïve" to "exhausted senescent" T cells: when markers predict functionality[J]. Cytometry A, 2014, 85: 25-35. doi:  10.1002/cyto.a.22351
    [10] Hand TW, Cui W, Jung YW, et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival[J]. Proc Natl Acad Sci USA, 2010, 107: 16601-16606. doi:  10.1073/pnas.1003457107
    [11] Zhou Y, Zhang Y, Han J, et al. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases[J]. J Transl Med, 2020, 18: 131. doi:  10.1186/s12967-020-02289-w
    [12] Leslie NR, Longy M. Inherited PTEN mutations and the prediction of phenotype[J]. Semin Cell Dev Biol, 2016, 52: 30-38. doi:  10.1016/j.semcdb.2016.01.030
    [13] Chen L, Guo D. The functions of tumor suppressor PTEN in innate and adaptive immunity[J]. Cell Mol Immunol, 2017, 14: 581-589. doi:  10.1038/cmi.2017.30
    [14] Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease[J]. Hum Mol Genet, 1997, 6: 1383-1387. doi:  10.1093/hmg/6.8.1383
    [15] Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome[J]. J Surg Oncol, 2015, 111: 125-130. doi:  10.1002/jso.23735
    [16] Daly MB, Pilarski R, Yurgelun MB, et al. NCCN Guide-lines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18: 380-391. doi:  10.6004/jnccn.2020.0017
    [17] Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice[J]. Proc Natl Acad Sci USA, 2001, 98: 10320-10325. doi:  10.1073/pnas.171060098
    [18] Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin[J]. Cancer Res, 2008, 68: 7066-7072. doi:  10.1158/0008-5472.CAN-08-0922
    [19] Ross-Innes CS, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma[J]. Nat Genet, 2015, 47: 1038-1046. doi:  10.1038/ng.3357
    [20] Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma[J]. CA Cancer J Clin, 2013, 63: 232-248. doi:  10.3322/caac.21185
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Article Metrics

    Article views (2756) PDF downloads(33) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return